Crossmark

Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)

Crossref DOI link: https://doi.org/10.1186/s13014-024-02577-5

Published Online: 2025-01-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tokito, Takaaki

Yamada, Kazuhiko

Ishii, Hidenobu

Takiguchi, Yuichi

Saito, Go

Minato, Koichi

Imai, Hisao

Tanaka, Hiroshi

Miura, Satoru

Watanabe, Kageaki

Koreeda, Yoshifusa

Ono, Akira

Furuya, Naoki

Misumi, Toshihiro

Hayakawa, Kazushige

Ogo, Etsuyo

Okamoto, Hiroaki
Clinical Trials ^BETA

Clinical trials referenced in this document:

umin000022431 at UMIN Japan

Documents that mention this clinical trial

Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)
https://doi.org/10.1186/s13014-024-02577-5
License Information

Text and Data Mining valid from 2025-01-04

Version of Record valid from 2025-01-04
More Information

Article History

Received: 14 August 2024

Accepted: 27 December 2024

First Online: 4 January 2025

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and Japan’s Clinical Trials Act. The protocol was registered with the University Hospital Medical Information Network, Japan (protocol identification number: UMIN000022431). All patients provided written informed consent.

: All patients provided consent for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below